4//SEC Filing
DeLong Mark Jeffrey 4
Accession 0001127602-24-022070
CIK 0001492422other
Filed
Aug 12, 8:00 PM ET
Accepted
Aug 13, 4:13 PM ET
Size
6.7 KB
Accession
0001127602-24-022070
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-08-12−5,201→ 14,799 totalExercise: $13.85Exp: 2029-02-27→ Common Stock (5,201 underlying) - Exercise/Conversion
Common Stock
2024-08-12$13.85/sh+5,201$72,034→ 60,395 total
Footnotes (2)
- [F1]This includes 501 shares from 04/30/2024 ESPP purchase.
- [F2]This option was granted on February 8, 2019 and fully vested.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001856078
Filing Metadata
- Form type
- 4
- Filed
- Aug 12, 8:00 PM ET
- Accepted
- Aug 13, 4:13 PM ET
- Size
- 6.7 KB